KT Keenova Therapeutics plc Stock: price and directors' dealings · United States · SEC (Form 4)Track the Keenova Therapeutics plc stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). The latest transaction was filed on 23 July 2026 (Retenue fiscale). Among the most active insiders: Silver Point Capital L.P.. Every trade is openly available.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 23 July 2026
All Executives31 Thresholds0 Prospectus0 Other0
Declarations 31 total
● EVP & CHRO · Executives · 21 Jul 2026
763 shares Ordinary Shares SEC:0001104659-26-086328:0
● EVP & Chief Info Officer · Executives · 21 Jul 2026
328 shares Ordinary Shares SEC:0001104659-26-086326:0
● EVP & Chief Compliance Officer · Executives · 21 Jul 2026
571 shares Ordinary Shares SEC:0001104659-26-086329:0
◇ Director · Executives · 2 Jun 2026
2,685 shares Ordinary Shares SEC:0001104659-26-084773:0
● Director · Executives · 2 Jun 2026
619 shares Ordinary Shares SEC:0001104659-26-084773:1
◇ Director · Executives · 2 Jun 2026
4,882 shares Ordinary Shares SEC:0001104659-26-070524:0
◇ Director · Executives · 2 Jun 2026
2,685 shares Ordinary Shares SEC:0001104659-26-070520:0
● Director · Executives · 2 Jun 2026
619 shares Ordinary Shares SEC:0001104659-26-070520:1
◇ Director · Executives · 2 Jun 2026
4,882 shares Ordinary Shares SEC:0001104659-26-070521:0
◇ Director · Executives · 2 Jun 2026
3,580 shares Ordinary Shares SEC:0001104659-26-070525:0
● Director · Executives · 2 Jun 2026
825 shares Ordinary Shares SEC:0001104659-26-070525:1
◇ EVP & CHRO · Executives · 23 Apr 2026
1,523 shares Ordinary Shares SEC:0001104659-26-048785:0
◇ EVP & Chief Compliance Officer · Executives · 23 Apr 2026
1,305 shares Ordinary Shares SEC:0001104659-26-048781:0
◇ EVP & Chief Info Officer · Executives · 23 Apr 2026
1,137 shares Ordinary Shares SEC:0001104659-26-048782:0
▲ 10% Owner · Executives · 15 Apr 2026
275,000 shares @ US$88.50 39.6% of flow Common Stock SEC:0001193125-26-161818:0
Canonical exit: 14 Jul 2026 (T+90) ▲ 10% Owner · Executives · 17 Apr 2026
410,000 shares @ US$90.50 60.4% of flow Common Stock SEC:0001193125-26-161818:1
Canonical exit: 16 Jul 2026 (T+90) 33,651 shares Ordinary Shares SEC:0001493152-26-006443:0
250,000 shares @ US$92.25 18.4% of flow Common Stock SEC:0001193125-26-009126:0
Canonical exit: 7 Apr 2026 (T+90) ◇ EVP, Qual & Ops, Spec Brands · Executives · 1 Jan 2026
2,055 shares Ordinary Shares SEC:0001104659-26-000783:0
◇ EVP & CLO and Corp Sec · Executives · 1 Jan 2026
6,576 shares Ordinary Shares SEC:0001104659-26-000784:0
◇ President and CEO · Executives · 1 Jan 2026
32,878 shares Ordinary Shares SEC:0001104659-26-000782:0
◇ Director · Executives · 1 Jan 2026
4,384 shares Ordinary Shares SEC:0001104659-26-000785:0
◇ EVP & Chief Transformation OFC · Executives · 1 Jan 2026
6,576 shares Ordinary Shares SEC:0001104659-26-000781:0
◇ EVP & Chief Commercial Officer · Executives · 1 Jan 2026
6,576 shares Ordinary Shares SEC:0001104659-26-000780:0
◇ Director · Executives · 1 Jan 2026
1,808 shares Ordinary Shares SEC:0001104659-26-000779:0
25 of 31 declarations
Load more (6 remaining) 关于 Keenova Therapeutics plc Keenova Therapeutics plc 是一家生物制药公司，专注于开发严重疾病的创新疗法。它在纳斯达克上市，股票代码为 KOVA。